Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Bucindolol
2. Mj 13105
1. 70369-47-0
2. Gencaro
3. Bucindolol Hcl
4. Bucindolol Hydrochloride [usan]
5. O-(2-hydroxy-3-((2-indol-3-yl-1,1-dimethylethyl)amino)propoxy)benzonitrile Monohydrochloride
6. Mj 13,105-1
7. Bucindolol (hydrochloride)
8. Sh683g4qii
9. 2-(2-hydroxy-3-((2-(3-indolyl)-1,1-dimethylethyl)amino)propoxy)benzonitrile Hydrochloride
10. 70369-47-0 (hcl)
11. Mj-13105-1
12. Benzonitrile, 2-(2-hydroxy-3-((2-(1h-indol-3-yl)-1,1-dimethylethyl)amino)propoxy)-, Monohydrochloride
13. Bucindolol Hydrochloride (usan)
14. Unii-sh683g4qii
15. Mj 13105-1
16. 2-[2-hydroxy-3-[[2-(3-indolyl)-1,1-dimethylethyl]amino]propoxy]benzonitrile Hydrochloride
17. Schembl124403
18. Chembl2107546
19. Dtxsid50990563
20. Bucindolol Hydrochloride [mi]
21. Akos030242702
22. Sb16899
23. Bucindolol Hydrochloride [mart.]
24. Bucindolol Hydrochloride [who-dd]
25. D03170
26. Q27289211
27. 2-(2-hydroxy-3-{[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino}propoxy)benzonitrile--hydrogen Chloride (1/1)
28. 2-[2-hydroxy-3-[[1-(1h-indol-3-yl)-2-methylpropan-2-yl]amino]propoxy]benzonitrile;hydrochloride
| Molecular Weight | 399.9 g/mol |
|---|---|
| Molecular Formula | C22H26ClN3O2 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 8 |
| Exact Mass | 399.1713548 g/mol |
| Monoisotopic Mass | 399.1713548 g/mol |
| Topological Polar Surface Area | 81.1 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 515 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Adrenergic beta-Antagonists
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (See all compounds classified as Adrenergic beta-Antagonists.)
Sympathomimetics
Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters. (See all compounds classified as Sympathomimetics.)
Vasodilator Agents
Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)
Adrenergic alpha-1 Receptor Antagonists
Drugs that bind to and block the activation of ADRENERGIC ALPHA-1 RECEPTORS. (See all compounds classified as Adrenergic alpha-1 Receptor Antagonists.)
ABOUT THIS PAGE
A Bucindolol Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Bucindolol Hydrochloride, including repackagers and relabelers. The FDA regulates Bucindolol Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Bucindolol Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Bucindolol Hydrochloride supplier is an individual or a company that provides Bucindolol Hydrochloride active pharmaceutical ingredient (API) or Bucindolol Hydrochloride finished formulations upon request. The Bucindolol Hydrochloride suppliers may include Bucindolol Hydrochloride API manufacturers, exporters, distributors and traders.
Bucindolol Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Bucindolol Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Bucindolol Hydrochloride GMP manufacturer or Bucindolol Hydrochloride GMP API supplier for your needs.
A Bucindolol Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Bucindolol Hydrochloride's compliance with Bucindolol Hydrochloride specifications and serves as a tool for batch-level quality control.
Bucindolol Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Bucindolol Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Bucindolol Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Bucindolol Hydrochloride EP), Bucindolol Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Bucindolol Hydrochloride USP).
LOOKING FOR A SUPPLIER?
